Business
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in
About this update from Lyell Immunopharma, Inc.
[{"type":"image","alt":"Lyell Immunopharma, Inc","displaySize":"","headline":null,"caption":"Lyell Immunopharma, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":222,"url":"https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gyyLnTdzLBmCtbGQjs4MFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.","length":284,"tagName":"p"}]},{"val":[{"type":"text","content":"Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in the third- or later-line setting.","length":250,"tagName":"p"}]},{"val":[{"type":"text","content":"LYL314 clinical supply now manufactured at Lyell’s LyFE Manufacturing Center™, following successful technology transfer and clearance by the FDA of an Investigational New Drug Amendment.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Remain on track to initiate a pivotal trial of LYL314 in the third- or later-line setting in mid-2025 and expect to initiate a pivotal trial in the second-line setting by early 2026.","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $330.1 million as of March 31, 2025 support advancing pipeline into 2027 through multiple clinical milestones.","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1069,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025. Lyell’s lead clinical ...